Skip to main content
main-content

Oncology

ASCO 2019

medwireNews was at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA, bringing you expert video interviews.

Expert interviews

04-06-2019 | Breast cancer | Video

ASCO 2019: Low-fat diet linked to reduced risk of breast cancer mortality

Rowan Chlebowski discusses the latest update from the Women’s Health Initiative Dietary Modification clinical trial showing the positive impact of a healthy diet on the risk of breast cancer death in postmenopausal women. He also touches upon how the metabolic syndrome may modify this risk (5:52).

04-06-2019 | Prostate cancer | Video

ASCO 2019: Enzalutamide addition prolongs survival in metastatic CSPC setting

Ian Davis takes us through the potentially practice-changing results of the phase III ENZAMET trial evaluating the addition of enzalutamide to standard of care in men with castration-sensitive prostate cancer (3:04).

03-06-2019 | Gastrointestinal cancer | Video

ASCO 2019: Olaparib maintenance improves BRCA1/2-positive pancreatic cancer outcomes

Hedy Kindler presents the phase III POLO trial of maintenance therapy with the PARP inhibitor olaparib in metastatic pancreatic cancer patients harbouring germline mutations in BRCA1 or BRCA2 (3:47).

03-06-2019 | Gastrointestinal cancer | Video

ASCO 2019: Low-dose chemotherapy a valid option for older gastro-oesophageal cancer patients

Peter Hall reports on the GO2 trial that aimed to optimise chemotherapy with oxaliplatin and capecitabine in elderly and frail individuals with advanced gastro-oesophageal cancer (1:40).

02-06-2019 | Breast cancer | Video

ASCO 2019: Ribociclib addition boosts OS in premenopausal advanced breast cancer patients

Sara Hurvitz summarises the findings of the phase III MONALEESA-7 trial investigating the addition of ribociclib to endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer (3:21).

02-06-2019 | Prostate cancer | Video

ASCO 2019: TITAN shows survival benefit with apalutamide in metastatic CSPC

Anders Bjartell outlines the main results of the placebo-controlled TITAN trial of apalutamide in men with castration-sensitive prostate cancer receiving androgen deprivation therapy (2:19).

Notable number of patients taking immune checkpoint inhibitors hospitalized with irAEs

Doctor_hospital bed

Patients receiving immune checkpoint inhibitor treatment have an increased risk for being hospitalized with immune-related adverse events, particularly if they are older or taking combination treatments, researchers report.

CASPIAN: Durvalumab addition boosts SCLC survival

IV drip 2

Adding durvalumab to first-line chemotherapy significantly improves the overall survival of patients with extensive-stage small-cell lung cancer, a phase III trial shows.

Elevated cardiovascular risk seen in survivors of most common cancers

New Content Item

Survivors of the 20 most common site-specific cancers, including lung and prostate, are at increased risk for cardiovascular disease in the years that follow diagnosis and treatment, show data published in The Lancet.

Latest news

20-09-2019 | Oncology | News | Article

Adding carboplatin to cabazitaxel benefits men with mCRPC

Phase I/II research published in The Lancet Oncology shows that combining cabazitaxel with carboplatin has the potential to prolong progression-free survival in men with metastatic castration-resistant prostate cancer.

18-09-2019 | Oncology | News | Article

Nivolumab confers NSCLC survival advantage over 5 years

Individuals with advanced non-small-cell lung cancer continue to derive a long-term survival benefit from second- or later-line treatment with nivolumab versus docetaxel, according to 5-year results from the CheckMate 017 and 057 trials.

18-09-2019 | Oncology | News | Article

Trilaciclib shows myelopreservation benefits in patients with SCLC

Trilaciclib affords myelopreservation in individuals with small-cell lung cancer treated with first-line chemotherapy, without impacting treatment efficacy, research indicates.

16-09-2019 | Oncology | News | Article

Special NSCLC populations can benefit from nivolumab plus ipilimumab

Non-small-cell lung cancer patients with poor performance status or comorbidity experience a similar adverse event rate to those with normal performance status when treated with nivolumab plus ipilimumab, say researchers.

Cabazitaxel–Carboplatin May Have ‘Clinically Beneficial Role’ For Metastatic CRPC

Adding carboplatin to cabazitaxel may improve progression-free survival for patients with metastatic castration-resistant prostate cancer

Read the full story on ESMO's oncologyPRO educational website (for registered ESMO members).





Twitter Icon Follow medwireNews

Click here
Image Credits